Key result
A fixed-dose combination of olmesartan 40 mg and chlorthalidone 12.5 mg significantly reduced systolic blood pressure by 36.4 mmHg and diastolic blood pressure by 18.27 mmHg from baseline after 60 days.
Why the study?
Does a fixed dose combination of olmesartan 40 mg and chlorthalidone 12.5 mg reduce blood pressure in hypertensive patients uncontrolled on olmesartan monotherapy?
Does a fixed dose combination of olmesartan 40 mg and chlorthalidone 12.5 mg reduce blood pressure in hypertensive patients uncontrolled on olmesartan monotherapy?
Mean Difference: -36.4
Absolute Event Rate: 142.7% vs 179.1%
p-value: p=<0.0001
A once-daily fixed-dose combination of olmesartan 40 mg and chlorthalidone 12.5 mg significantly reduces both systolic and diastolic blood pressure in patients with hypertension uncontrolled on olmesartan monotherapy.
May support use in olmesartan-uncontrolled hypertension; leaves open need for RCTs to confirm outcomes.
Hypertension is the most prevalent chronic disease in India and its prevalence is rapidly increasing among urban and rural populations. Reducing blood pressure can decrease cardiovascular risk and all cause mortality. This study was conducted to assess the efficacy and safety of fixed dose combination of Olmesartan 40 mg and Chlorthalidone12.5mg. 30 hypertensive patients having systolic blood pressure ? 160 mmHg and diastolic blood pressure ?100 mmHg who were uncontrolled on monotherapy with olmesartan were enrolled in this study. The treatment period was of 60 days and patients were administered once daily fixed dose combination of Olmesartan40 mg and Chlorthalidone 12.5 mg. Patients were evaluated on 15th, 30th and 60th days of treatment.There was statistically significant (p<0.0001) decrease in systolic blood pressure from baseline to 15th, 30th and 60thday of treatmentmean±SD (179.1±13.38 mmHg vs. 169.3±13.05, 154.3±13.31, and 142.7±6.91mmHg) respectively. Similarly the diastolic blood pressure (DBP) was significantly (p<0.0001) reduced from the baseline to the 15th, 30th and 60thday of treatment (94.97±5.75mmHg vs.86.67±4.79, 80.33±1.82 and 76.7±4.32 mmHg respectively). Thus fixed dose combination of Olmesartan and Chlorthalidonewas found to be effective and safe option for the optimal management of hypertension.J MEDICINE January 2017; 18 (1) : 6-9
No takes yet. Share an insight, caveat, or question.
Khanna et al. (2017) studied Hypertension (n=30). Olmesartan and Chlorthalidone vs. Baseline was evaluated on Systolic Blood Pressure at 60 days (MD -36.4, p=<0.0001). A fixed-dose combination of olmesartan 40 mg and chlorthalidone 12.5 mg significantly reduced systolic blood pressure by 36.4 mmHg and diastolic blood pressure by 18.27 mmHg from baseline after 60 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: